(2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-3-yl)methanol | 152895-57-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-3-yl)methanol
• 英文别名: 2,3-Dihydro-1,4-dioxino[2,3-b]pyridine-3-methanol；2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-3-ylmethanol
• CAS: 152895-57-3
• 化学式: C₈H₉NO₃
• 分子量: 167.164
• InChiKey: RHHZZOVOFZSEJI-UHFFFAOYSA-N

物化性质

• 沸点：
  312.7±30.0 °C(Predicted)
• 密度：
  1.284±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  51.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-3-yl)methanol 在 吡啶 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 56.0h， 生成 3-(2,3-Dihydro-1,4-dioxino[2,3-b]pyridine)yl-N-methyl-methanamine
  参考文献：
  名称：

  有效合成2-和3-取代的2,3-二氢[1,4]二氧杂[2,3- b ]吡啶衍生物

  摘要：

  描述了一种通用的新方法，该方法通过使用易于获得的试剂的Smiles重排以三步合成2-取代的2,3-二氢[1,4]二恶英[2,3- b ]吡啶B。据报道，研究表明了实验条件对反应进程的影响。

  DOI：

  10.1016/j.tet.2004.06.041
• 作为产物：
  描述：

  3-羟基-2-硝基吡啶 在 aluminum oxide 、 sodium hydride 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 85.5h， 生成 (2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-3-yl)methanol
  参考文献：
  名称：

  有效合成2-和3-取代的2,3-二氢[1,4]二氧杂[2,3- b ]吡啶衍生物

  摘要：

  描述了一种通用的新方法，该方法通过使用易于获得的试剂的Smiles重排以三步合成2-取代的2,3-二氢[1,4]二恶英[2,3- b ]吡啶B。据报道，研究表明了实验条件对反应进程的影响。

  DOI：

  10.1016/j.tet.2004.06.041

文献信息

• Compounds for treating impaired fundic relaxation
  申请人：——

  公开号：US20040019051A1

  公开（公告）日：2004-01-29

  The present invention concerns compounds of formula (I) a stereochemically isomeric form thereof, an N-oxide form thereof or a pharma-ceutically acceptable acid addition salt thereof, wherein —a 1 ═a 2 —a 3 ═a 4 — is a bivalent radical wherein one or two of a 1 to a 4 are nitrogen and the remaining a 1 to a 4 are —CH═; —Z 1 —Z 2 — is a bivalent radical; —A— is a bivalent radical of formula —N(R 6 )—Alk 2 — or a 5, 6 or 7-membered saturated heterocycle containing one or two nitrogen atoms; R 1 , R 2 and R 3 are each independently selected from hydrogen, C 1-6 alkyl, hydroxy, halo and the like; Alk 1 and Alk 2 are optionally substituted C 1-6 alkanediyl; R 5 is a radical of formula (d-1), (d-2), (d-3), (d-4), (d-5) wherein n is 1 or 2; p 1 is 0, and p 2 is 1 or 2; or p 1 is 1 or 2, and p 2 is 0; X is oxygen, sulfur or ═NR 9 ; Y 2 is oxygen or sulfur; R 7 is hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, phenyl or phenylmethyl; R 8 is C 1-6 alkyl, C 3-6 cycloalkyl phenyl or phenylmethyl; R 9 is cyano, C 1-6 alkyl, C 3-6 cyclo-alkyl, C 1-6 alkyloxycarbonyl or aminocarbonyl; R 10 is hydrogen or C 1-6 alkyl; and Q is a bivalent radical. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating conditions which are related to disturbed fundic accomodation. 1

  本发明涉及式（I）的化合物，其立体化学异构体形式，N-氧化物形式或药学上可接受的酸加合物盐形式，其中-a1═a2-a3═a4-是一个双价基团，其中a1到a4中的一个或两个是氮，其余的a1到a4是-CH═；-Z1—Z2-是一个双价基团；-A-是公式-N（R6）-Alk2-或含有一个或两个氮原子的5、6或7元饱和杂环的双价基团；R1、R2和R3各自独立地选自氢、C1-6烷基、羟基、卤素等；Alk1和Alk2是可选取代的C1-6烷二基；R5是公式（d-1）、（d-2）、（d-3）、（d-4）、（d-5）的基团，其中n为1或2；p1为0，p2为1或2；或p1为1或2，p2为0；X为氧、硫或═NR9；Y2为氧或硫；R7为氢、C1-6烷基、C3-6环烷基、苯基或苯甲基；R8为C1-6烷基、C3-6环烷基、苯基或苯甲基；R9为氰基、C1-6烷基、C3-6环烷基、C1-6烷氧羰基或氨基羰基；R10为氢或C1-6烷基；Q为双价基团。公开了制备所述产品的方法，包含所述产品的配方以及其用作药物的用途，特别是用于治疗与干扰胃底容积有关的疾病。
• 1,4-Dioxino 2,3-b pyridine derivatives having serotonergic activity
  申请人：Akzo Nobel N.V.

  公开号：EP0559285A1

  公开（公告）日：1993-09-08

  This invention is concerned with 1,4-dioxino[2,3-b]-pyridine derivatives having formula I wherein each of the groups R is independently selected from hydrogen, hydroxy, lower alkyl, lower alkoxy, CF₃, and halogen; R₁ is hydrogen or lower alkyl; n is 2, 3, or 4; X is CH₂, C=O, or SO₂; and Y is substituted or unsubstituted 1,2-phenylene, -(CH₂)₄-, -CH₂CR₂R₃-, or -CH₂CR₂R₃CH₂-, in which R₂ and R₃ are independently hydrogen or lower alkyl, or together 1,4-butanediyl or 1,5-pentanediyl; or pharmaceutically acceptable salts thereof. The compounds according to the invention are strong serotonin ligands with preference for the 5HT1A receptor and may, therefore, find application as anti-depressants or as a drug in combating anxiety disorders.

  本发明涉及具有式I的1,4-二氧杂[2,3-b]-吡啶衍生物，其中R的每个基团独立地选自氢、羟基、低级烷基、低级烷氧基、CF₃和卤素；R₁为氢或低级烷基；n为2、3或4；X为CH₂、C=O或SO₂；Y为取代或未取代的1,2-苯撑基、-(CH₂)₄-、-CH₂CR₂R₃-或-CH₂CR₂R₃CH₂-，其中R₂和R₃独立地为氢或低级烷基，或一起为1,4-丁二基或1,5-戊二基；或其药学上可接受的盐。本发明中的化合物是强的5-羟色胺配体，具有对5HT1A受体的选择性，因此可以作为抗抑郁剂或用于对抗焦虑症的药物。
• Synthesis of novel 3-substituted-2,3-dihydro-1,4-dioxino[2,3-b]pyridines as potential new scaffolds for drug discovery: selective introduction of substituents on the pyridine ring
  作者：Jesús Alcázar、José M. Alonso、José M. Bartolomé、Laura Iturrino、Encarnación Matesanz

  DOI：10.1016/j.tetlet.2003.10.005

  日期：2003.12

  Selective introduction of substituents on 3-substituted-2,3-dihydro-1,4-dioxino[2,3-b]pyridine at the pyridine ring was achieved using electrophilic aromatic substitution and addition–elimination reactions. In all the examples, functionalization at the 3-position was maintained. For this reason, the products disclosed in this paper could be useful as potential scaffolds for drug discovery and combinatorial

  使用亲电子芳族取代和加成-消除反应可实现在吡啶环上的3-取代-2,3-二氢-1,4-二恶英[2,3- b ]吡啶上选择性引入取代基。在所有实施例中，维持在3-位的官能化。因此，本文中公开的产品可用作药物发现和组合化学的潜在支架。
• Compounds for treating fundic disaccomodation
  申请人：Emelen Van Kristol

  公开号：US20060142318A1

  公开（公告）日：2006-06-29

  The present invention concerns compounds of formula (I) a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, wherein -a 1 =a 2 -a 3 =a 4 - is a bivalent radical wherein one or two of a 1 to a 4 are nitrogen and the remaining a 1 to a 4 are —CH═; -Z 1 -Z 2 - is a bivalent radical; -A- is a bivalent radical of formula —N(R 6 )-Alk 2 - or a 5, 6 or 7-membered saturated heterocycle containing one or two nitrogen atoms; R 1 , R 2 and R 3 are each independently selected from hydrogen, C 1-6 alkyl, hydroxy, halo and the like; Alk 1 and Alk 2 are optionally substituted C 1-6 alkanediyl; R 5 is a radical of formula wherein n is 1 or 2; p 1 is 0, and p 2 is 1 or 2; or p 1 is 1 or 2, and p 2 is 0; X is oxygen, sulfur or ═NR 9 ; Y 2 is oxygen or sulfur; R 7 is hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, phenyl or phenylmethyl; R 8 is C 1-6 alkyl, C 3-6 cycloalkyl phenyl or phenylmethyl; R 9 is cyano, C 1-6 alkyl, C 3-6 cycloalkyl, C 1-6 alkyloxycarbonyl or aminocarbonyl; R 10 is hydrogen or C 1-6 alkyl; and Q is a bivalent radical. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating conditions which are related to disturbed fundic accomodation.

  本发明涉及式（I）化合物，其立体化学异构体，其N-氧化物形式或其药学上可接受的酸加成盐，其中-a1 = a2-a3 = a4-是一个双价基团，其中a1到a4中的一个或两个是氮，其余的a1到a4是-CH═; -Z1-Z2-是一个双价基团; -A-是一个式为-N（R6）-Alk2-的双价基团或含有一个或两个氮原子的5、6或7元饱和杂环; R1，R2和R3分别独立选择自氢，C1-6烷基，羟基，卤素等; Alk1和Alk2是可选取代的C1-6烷二基; R5是一个式为的基团，其中n为1或2; p1为0，p2为1或2; 或p1为1或2，p2为0; X是氧，硫或═NR9; Y2是氧或硫; R7是氢，C1-6烷基，C3-6环烷基，苯基或苯甲基; R8是C1-6烷基，C3-6环烷基苯基或苯甲基; R9是氰基，C1-6烷基，C3-6环烷基，C1-6烷氧羰基或氨基羰基; R10是氢或C1-6烷基; Q是一个双价基团。公开了制备所述产品的过程，包括所述产品的制剂及其作为药物的用途，特别是用于治疗与干扰胃底容纳有关的疾病。
• Identification of dihydroquinolizinone derivatives with cyclic ether moieties as new anti-HBV agents
  作者：Xiaoyu Qin、Lu Yang、Xican Ma、Bin Jiang、Shuo Wu、Apeng Wang、Shijie Xu、Wenhao Wu、Huijuan Song、Na Du、Kai Lv、Yuhuan Li、Mingliang Liu

  DOI：10.1016/j.ejmech.2022.114518

  日期：2022.8

  Pharma, was expected to realize the “functional cure of HBV”. However, it was dismissed in phase I clinical trial due to its neurotoxicity. In this study, a series of new DHQ derivatives containing a cyclic ether or benzo-fused (cyclic) ether moiety were designed, synthesized and evaluated for their in vitro activity. Many of them exhibited potent inhibition activity against HBsAg, HBeAg and HBV DNA

  罗氏制药研发的二氢喹啉酮（DHQ）候选药物RG7834有望实现“HBV的功能性治愈”。然而，由于其神经毒性，它在 I 期临床试验中被驳回。在这项研究中，设计、合成了一系列含有环醚或苯并稠合（环）醚部分的新型 DHQ 衍生物，并对其体外活性进行了评估。其中许多对 HBsAg、HBeAg 和 HBV DNA 表现出有效的抑制活性。更重要的是，在体外神经毒性评价中，RG7834处理的PC12细胞大部分变圆，甚至萎缩，神经突消失；相比之下，大多数用( 2ʹS, 6S )-1a处理的细胞，显示出与对照组相似的形态结构，具有清晰可见的神经突，表明( 2ʹS, 6S )-1a可以改善神经毒性。对DHQs结构-神经毒性关系的首次研究为DHQs的未来发展铺平了道路。